Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCX063 pharmacokinetics in chronic kidney disease
ACTRN12623000732684Phase 2Withdrawn
- Sponsor
- Certa Therapeutics
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of OCX-063 in chronic kidney disease (CKD) (3 arms), sponsored by Certa Therapeutics. Primary endpoint: Pharmacokinetic profile of OCX063. Planned start Sep 2023; status: withdrawn.
02
Drugs
OCX-063
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on ACTRN12623000732684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000732684.